| Theme | Tumors and bone mineral metabolism | |
|---|---|---|
| Title | Tumor-induced osteomalacia and FGF23 | |
| Publish Date | 2014/01 | |
| Author | Seiji Fukumoto | Division of Nephrology & Endocrinology, Department of Medicine, University of Tokyo Hospital |
| [ Summary ] | Tumor-induced osteomalacia is one of paraneoplastic syndromes. Fibroblast growth factor 23 (FGF23) which was identified as a causative factor for TIO reduces serum phosphate by inhibiting proximal tubular phosphate reabsorption and intestinal phosphate absorption by reducing 1,25-dihydroxyvitamin D level. It has been reported that tumors responsible for TIO overexpress FGF23. In addition, patients with TIO exhibit high circulatory levels of FGF23 and this elevated FGF23 rapidly decreases after resection of responsible tumors for TIO. TIO is cured by complete removal of responsible tumors. On the other hand, several methods to inhibit FGF23 activity are considered as novel therapeutic measures for patients with TIO whose tumors cannot be removed. | |